We describe a case of non-menstrual streptococcal toxic shock syndrome requiring high doses of noradrenaline. The intravenous administration of pooled immunoglobulin was associated with improved haemodynamics and weaning of vasoconstrictors.
Toxic shock syndrome (TSS) is an acute, febrile non-bacteraemic infective syndrome associated with diffuse macular rash, subsequent desquamation of skin and multiple organ dysfunction. It was first described in association with staphylococcal infection 1 , but recently it has also been identified in group A β-haemolytic streptococcal infection 2, 3 . Although both staphylococci and streptococci have been associated with TSS, the exact mechanism by which they mediate it is unclear [4] [5] . The toxin responsible for staphylococcal TSS has been recognized as Toxic Shock Syndrome toxin-1 (TSST-1) 4 , while streptococcal pyrogenic exotoxin A has been implicated in streptococcal TSS 6 . The pathogenesis of TSS may be multifactorial. In addition to direct toxic effects of toxins, toxin-induced immunosuppression and release of endogenous mediators like interleukins (IL) and tumour necrosis factor (TNF) may be responsible for many of the systemic sequelae in TSS 4, 7, 8 . Other important factors are host immunity and local tissue conditions for optimal production of toxins 4 . An adjunctive passive immunotherapy with neutralization of toxins might be beneficial in these patients 9 . We describe a case of non-menstrual TSS, treated with intravenous pooled immunoglobulin, and present haemodynamic data showing a possible beneficial effect.
CASE HISTORY
A 49-year-old man (height 165 cm, weight ~120 kg) was admitted to the Accident and Emergency department with a three-day history of fever, nausea, vomiting and diarrhoea, associated with an apparent cellulitis of the left elbow, for which he had been prescribed oral erythromycin. His previous medical history included lumbar spinal stenosis for which he was taking slow release diclofenac sodium 100 mg once a day. He was allergic to penicillin and had no history of recent foreign travel, nor tick or other insect bites.
On examination, he appeared acutely ill, confused and agitated with an axillary temperature of 39°C, blood pressure 80/40 mmHg (supine), pulse rate 118/min, and a respiratory rate of 36 breaths per minute with reduced air entry on both sides of the chest. A macular erythematous rash was seen over the trunk and all four extremities and a florid, red, blistering swelling of the left elbow was noted. The abdominal and rectal examination was normal. Initial laboratory investigations showed a haemoglobin concentration of 14.2 g.dl -1 , white cell count of 18.5x10 9 .l -1 , platelet count 123x10 9 .l -1 , serum sodium 132 mmol.l -1 , potassium 3.5 mmol.l -1 , urea 28.1 mmol.l -1 , creatinine 562 µmol.l -1 , albumin 30 g.l -1 , total bilirubin 31 µmol.l -1 with abnormal liver enzymes and serum creatine kinase 1296 IU.l -1 (100% isoenzyme MM). Blood, urine and sputum cultures were taken and all subsequently showed no growth.
Initially, he was admitted to the general medical ward, where he was commenced on oxygen by facemask, intravenous fluid therapy and intravenous cefotaxime (1g 8 hourly) and metronidazole (500 mg 8 hourly). Despite these measures and an infusion of dobutamine (5 to 10 µg.kg -1 .min -1 ), systolic blood pressure fell to 60 mmHg with anuria. Twenty hours after hospital admission, he was transferred to the intensive care unit (ICU) and a pulmonary artery catheter was inserted. The initial findings were: cardiac index 8.33 l.min -1 .m -2 , systemic vascular resistance (SVR) 434 dyn.s.cm -5 , (SVRI 1046 dyn.s.cm -5 .m -2 ) and pulmonary capillary wedge pressure (PCWP) of 8 mmHg. The APACHE II score on admission was 29. Vigorous fluid resuscitation was continued, an infusion of noradrenaline commenced at a rate of 6 µg.min -1 and intravenous teicoplanin 400 mg daily added to his antibiotic therapy. Nine hours after ICU admission, increasing respiratory distress and confusion necessitated endotracheal intubation and ventilation. He was sedated with morphine and midazolam infusions. Chest X-ray showed diffuse interstitial infiltration with a PCWP of 12 mmHg.
Over the first 12 hours in the ICU, he received 6.5 litres of colloid and 4 litres of crystalloid solutions, during which blood pressure falls were associated with further decline in SVR necessitating an increase in the infusion rate of noradrenaline to 110 µg.min -1 . Although the urine output was restored to 100 to 200 ml.h -1 , the blood pressure remained labile. Fluid aspirated from the left elbow showed Gram positive cocci microscopically, but subsequent culture was negative, possibly because of antibiotic therapy. Laboratory investigations showed deteriorating hepatic function (total bilirubin 51 µmol.l -1 and ALT 142 IU.l -1 ) and thrombocytopenia (platelets 59x10 9 .l -1 ).
A diagnosis of toxic shock syndrome (Table 1) was made, and 0.4 g.kg -1 of pooled intravenous immunoglobulin (IVIG) was administered over six hours (Alphaglobulin-Alpha Therapeutic U.K. Limited, Bio Products Laboratory). Within 12 hours of completing the IVIG infusion, the SVR began increasing, allowing reduction of noradrenaline to 88 µg.min -1 and further substantial reductions were seen over the next 24 hours (Figure 1 ). On day 3, the IVIG infusion was repeated with similar but less dramatic effect. The clinical improvement continued with cessation of all inotropic and vasopressor support by day 7 and extubation on day 9. The characteristic desquamation of hands and feet began on day 10 and the patient was discharged from the ICU on day 14 with normal renal biochemistry. After three weeks of intravenous teicoplanin therapy he was discharged home on oral ciprofloxacin 500 mg 12 hourly and rifampicin 300 mg 12 hourly for a further six weeks.
Serological studies for staphylococcal and streptococcal markers were performed during clinical recovery. Antistaphylolysin antibody was consistently below the limits of detection. ASO titres showed a small increase from 240 U.ml -1 to 320 U.ml -1 from day 12 to day 17, but in the same period, anti-DNAase B increased from 1440 U.ml -1 to >5760 U.ml -1 , a level indicative of streptococcal infection.
DISCUSSION
Non and -B: ≥2 of the following signs renal impairment: creatinine ≥177 mmol.l -1 coagulopathy: platelets 100x10 9 .l -1 or disseminated intravascular coagulation liver involvement: ALT, AST or bilirubin levels greater than twice the normal adult respiratory distress syndrome (ARDS) generalized erythematous rash that may desquamate soft-tissue necrosis, e.g. necrotizing fasciitis, myositis, gangrene age in both sexes equally. The reported mortality is approximately 3.5% and 9% in menstrual and nonmenstrual cases respectively 10 . Successful management of TSS requires early treatment of the underlying condition and aggressive management of its lifethreatening cardiorespiratory manifestations. The treatment is to remove the focus of infection (if possible), appropriate antibiotics and early, vigorous fluid resuscitation. Inotropic and/or vasopressor support may also be required as in the case described. Protracted intensive therapy of multiple organ failure may be needed. The acute phase titres of antibodies to staphylococcal toxins in 83% of patients with TSS are 1:5 or less, in contrast to a titre of 1:100 or higher in the healthy adult population 11 . This may be a primary defect or secondary to the infection as a result of immunosuppressive effects of toxins 4, 7 . In either case, we postulate that passive immunotherapy as an adjunct to antibiotic therapy may be beneficial in both staphylococcal and streptococcal TSS, as neutralization assays have shown that there is crossreactivity of antibodies against staphylococcal and streptococcal pyrogenic toxins 12 . Commercially available immunoglobulin preparations have high levels of antibodies to common staphylococcal and streptococcal toxins and also antibodies to cytokines and interferons. IVIG therapy in TSS may exert a regulatory effect on B cells, T cells and natural killer cells, reducing the plasma concentrations of the endogenous mediators like TNF-α and IL-6 5, 13 .
Even though the list of currently approved medical indications for various IVIG products does not include sepsis or septic shock, they are widely used as prophylaxis and/or supplemental therapy 14 . Alejandria and co-workers (Cochrane Review 2001) reviewed the evidence of randomized controlled trials comparing IVIG with a control group that received placebo or no intervention in patients with bacterial sepsis or septic shock 15 . They have reported an overall reduction in mortality in patients who received polyclonal IVIG (n=492; RR=0.64; 95% CI 0.51 to 0.80), but not among patients who received monoclonal antibodies. They have concluded that polyclonal IVIG significantly reduces mortality and can be used as an adjuvant treatment for sepsis and septic shock. Adjunctive therapy with monoclonal IVIGs remains experimental. However, the failure to reduce mortality by IVIG in the score-based immunoglobulin treatment in sepsis study (SBITS), seriously dampens the hopes for IVIG therapy in sepsis or septic shock 16 .
In the literature, there are several case reports correlating clinical improvement with the administration of IVIG in TSS 5,17-20 . Barry and colleagues have reported a possible therapeutic benefit of IVIG in a case of streptococcal menstrual TSS, with complete reversal of vasospastic changes in fingers and improvement in respiratory status 17 . Non-menstrual streptococcal TSS in an alcoholic has also been successfully treated with IVIG therapy 20 . A comparative observational study of IVIG therapy in streptococcal TSS produced impressive results with an odds ratio for survival associated with IVIG therapy of 8.1 9 . This may be due to neutralization of bacterial exotoxins. This study adds to data from case reports suggesting an improved outcome associated with IVIG therapy in patients with streptococcal TSS. In our case, we believe that IVIG therapy was associated with significant improvement in vasomotor tone and clinical condition.
In conclusion, TSS is a rare medical emergency with severe and potentially fatal complications. As there is no definitive diagnostic test for TSS, a high index of suspicion supported by the case definitions (Tables 1 and 2) may be required to make the diagnosis. It is unlikely that a randomized controlled trial to test the use of this therapy can be performed. In the absence of such randomized controlled studies, data from observational studies and case reports could justify IVIG as an adjunctive therapy in TSS.
